These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 12667895)
41. The synaptic and nonsynaptic glycine transporter type-1 inhibitors Org-24461 and NFPS alter single neuron firing rate in the rat dorsal raphe nucleus. Further evidence for a glutamatergic-serotonergic interaction and its role in antipsychotic action. Papp A; Juranyi Z; Nagymajtenyi L; Matyus P; Harsing LG Neurochem Int; 2008 Jan; 52(1-2):130-4. PubMed ID: 17669555 [TBL] [Abstract][Full Text] [Related]
42. Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions. Hanuska A; Szénási G; Albert M; Koles L; Varga A; Szabo A; Matyus P; Harsing LG Neurochem Res; 2016 Feb; 41(1-2):73-85. PubMed ID: 26364050 [TBL] [Abstract][Full Text] [Related]
43. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats. Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471 [TBL] [Abstract][Full Text] [Related]
44. Augmentation of fear extinction by infusion of glycine transporter blockers into the amygdala. Mao SC; Lin HC; Gean PW Mol Pharmacol; 2009 Aug; 76(2):369-78. PubMed ID: 19411609 [TBL] [Abstract][Full Text] [Related]
46. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Nagy K; Marko B; Zsilla G; Matyus P; Pallagi K; Szabo G; Juranyi Z; Barkoczy J; Levay G; Harsing LG Neurochem Res; 2010 Dec; 35(12):2096-106. PubMed ID: 20725779 [TBL] [Abstract][Full Text] [Related]
47. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Tsai G; Ralph-Williams RJ; Martina M; Bergeron R; Berger-Sweeney J; Dunham KS; Jiang Z; Caine SB; Coyle JT Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8485-90. PubMed ID: 15159536 [TBL] [Abstract][Full Text] [Related]
48. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Kopec K; Flood DG; Gasior M; McKenna BA; Zuvich E; Schreiber J; Salvino JM; Durkin JT; Ator MA; Marino MJ Biochem Pharmacol; 2010 Nov; 80(9):1407-17. PubMed ID: 20637735 [TBL] [Abstract][Full Text] [Related]
49. Glycine taken up through GLYT1 and GLYT2 heterotransporters into glutamatergic axon terminals of mouse spinal cord elicits release of glutamate by homotransporter reversal and through anion channels. Raiteri L; Stigliani S; Siri A; Passalacqua M; Melloni E; Raiteri M; Bonanno G Biochem Pharmacol; 2005 Jan; 69(1):159-68. PubMed ID: 15588724 [TBL] [Abstract][Full Text] [Related]
50. Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment. Tanabe M; Takasu K; Yamaguchi S; Kodama D; Ono H Anesthesiology; 2008 May; 108(5):929-37. PubMed ID: 18431130 [TBL] [Abstract][Full Text] [Related]
51. Probing the modulation of acute ethanol intoxication by pharmacological manipulation of the NMDAR glycine co-agonist site. Debrouse L; Hurd B; Kiselycznyk C; Plitt A; Todaro A; Mishina M; Grant SG; Camp M; Gunduz-Cinar O; Holmes A Alcohol Clin Exp Res; 2013 Feb; 37(2):223-33. PubMed ID: 22934986 [TBL] [Abstract][Full Text] [Related]
52. Pre-synaptic glycine GlyT1 transporter--NMDA receptor interaction: relevance to NMDA autoreceptor activation in the presence of Mg2+ ions. Musante V; Summa M; Cunha RA; Raiteri M; Pittaluga A J Neurochem; 2011 May; 117(3):516-27. PubMed ID: 21348870 [TBL] [Abstract][Full Text] [Related]
53. Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors; interaction with antipsychotics. Bennett S; Gronier B Eur J Pharmacol; 2005 Dec; 527(1-3):52-9. PubMed ID: 16307739 [TBL] [Abstract][Full Text] [Related]
54. Electrophysiological evidence of increased glycine receptor-mediated phasic and tonic inhibition by blockade of glycine transporters in spinal superficial dorsal horn neurons of adult mice. Oyama M; Kuraoka S; Watanabe S; Iwai T; Tanabe M J Pharmacol Sci; 2017 Mar; 133(3):162-167. PubMed ID: 28302446 [TBL] [Abstract][Full Text] [Related]
55. Effect of Sarcosine (a Glycine Transport 1 Inhibitor) and Risperidone (an Atypical antipsychotic Drug) on MK-801 Induced Learning and Memory Deficits in Rats. Kumar V; Ahmad MA; Najmi AK; Akhtar M Drug Res (Stuttg); 2016 Jan; 66(1):11-7. PubMed ID: 25710578 [TBL] [Abstract][Full Text] [Related]
56. Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats. Balsara JJ; Jadhav SA; Gaonkar RK; Gaikwad RV; Jadhav JH Psychopharmacology (Berl); 2005 May; 179(3):597-605. PubMed ID: 15614572 [TBL] [Abstract][Full Text] [Related]
57. Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters. Harsing LG; Matyus P Brain Res Bull; 2013 Apr; 93():110-9. PubMed ID: 23266673 [TBL] [Abstract][Full Text] [Related]
58. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Smith G; Ruhland T; Mikkelsen G; Andersen K; Christoffersen CT; Alifrangis LH; Mørk A; Wren SP; Harris N; Wyman BM; Brandt G Bioorg Med Chem Lett; 2004 Aug; 14(15):4027-30. PubMed ID: 15225720 [TBL] [Abstract][Full Text] [Related]
59. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Harada K; Nakato K; Yarimizu J; Yamazaki M; Morita M; Takahashi S; Aota M; Saita K; Doihara H; Sato Y; Yamaji T; Ni K; Matsuoka N Eur J Pharmacol; 2012 Jun; 685(1-3):59-69. PubMed ID: 22542656 [TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]